Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia.
Rautenberg C, Stölzel F, Röllig C, Stelljes M, Gaidzik V, Lauseker M, Kriege O, Verbeek M, Unglaub JM, Thol F, Krause SW, Hänel M, Neuerburg C, Vucinic V, Jehn CF, Severmann J, Wass M, Fransecky L, Chemnitz J, Holtick U, Schäfer-Eckart K, Schröder J, Kraus S, Krüger W, Kaiser U, Scholl S, Koch K, Henning L, Kobbe G, Haas R, Alakel N, Röhnert MA, Sockel K, Hanoun M, Platzbecker U, Holderried TAW, Morgner A, Heuser M, Sauer T, Götze KS, Wagner-Drouet E, Döhner K, Döhner H, Schliemann C, Schetelig J, Bornhäuser M, Germing U, Schroeder T, Middeke JM. Rautenberg C, et al. Among authors: holderried taw. Blood Cancer J. 2021 Oct 4;11(10):164. doi: 10.1038/s41408-021-00558-5. Blood Cancer J. 2021. PMID: 34608129 Free PMC article. Clinical Trial.
The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma.
Holderried TAW, Fraccaroli A, Schumacher M, Heine A, Brossart P, Stelljes M, Klobuch S, Kröger N, Apostolova P, Finke J, Zeiser R, Heinicke T, Bornhäuser M, von Bergwelt-Baildon M, Tischer J, Wolf D. Holderried TAW, et al. Bone Marrow Transplant. 2019 Oct;54(10):1662-1667. doi: 10.1038/s41409-019-0498-0. Epub 2019 Mar 4. Bone Marrow Transplant. 2019. PMID: 30833743
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Zeiser R, et al. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. N Engl J Med. 2021. PMID: 34260836 Clinical Trial.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Among authors: holderried taw. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
39 results